| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 05/06/2004 | US20040086899 Compromises nuclelotide sequences coding polypeptides associated with elongation of fatty acid chains for treatment and prevention of skin, cardiovascular, inflammatory, gastrointestinal, respiratory system and bone disorders |
| 05/06/2004 | US20040086877 Multi-mode directi memory access controller and method |
| 05/06/2004 | US20040086846 Using bacterial artificial chromosomes to propagate/replicate viral nucleotide sequences; gene therapy and genetic vaccines |
| 05/06/2004 | US20040086525 Polynucleotide sequences of C. pneumoniae for use in preventing and treating Chlamydia infection |
| 05/06/2004 | US20040086522 Strategies to prevent autoimmune disease by vaccination with vaccines based upon Epstein-Barr virus |
| 05/06/2004 | US20040086502 Has a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for said antigen |
| 05/06/2004 | US20040086465 Aerosol suspension formulations which are free of chlorofluorocarbons comprising mometasone furoate, a dry powder surfactant and HFA 227, |
| 05/06/2004 | EP1415994A1 Retinal pigmented epithelium derived neurotrophic factor |
| 05/06/2004 | EP1415986A1 Spiro compounds |
| 05/06/2004 | EP1415983A1 5-amidino-n-(2-aminophenethyl)-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
| 05/06/2004 | EP1415773A1 Gripper |
| 05/06/2004 | EP1415647A1 "Long-acting beta-2 agonists ultrafine formulations" |
| 05/06/2004 | EP1414961A2 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 05/06/2004 | EP1414861A2 Humanized antibodies against icam-1, their production and uses |
| 05/06/2004 | EP1414849A2 Immune-modulating peptide |
| 05/06/2004 | EP1414841A1 Oligonucleotide-containing pharmacological compositions and their use |
| 05/06/2004 | EP1414825A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease |
| 05/06/2004 | EP1414812A1 Hydroxamic acid derivatives |
| 05/06/2004 | EP1414810A2 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| 05/06/2004 | EP1414804A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/06/2004 | EP1414802A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 05/06/2004 | EP1414790A1 Substituted n-acyl aniline derivatives, production and use thereof as medicaments |
| 05/06/2004 | EP1414525A2 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-n-methyl-isobutyramide |
| 05/06/2004 | EP1414522A2 Carbonic anhydrase inhibitors |
| 05/06/2004 | EP1414498A2 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 05/06/2004 | EP1414486A2 Use of glp-2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 05/06/2004 | EP1414484A1 Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome |
| 05/06/2004 | EP1414481A2 Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| 05/06/2004 | EP1414475A2 An herbal composition for the treatment and remedy of bronchial respiratory difficulties |
| 05/06/2004 | EP1414468A1 Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders |
| 05/06/2004 | EP1414466A1 Combinations for the treatment of inflammatory disorders |
| 05/06/2004 | EP1414460A1 Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor |
| 05/06/2004 | EP1414455A1 Isoquinoline inhibitors of p38 |
| 05/06/2004 | EP1414444A1 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists |
| 05/06/2004 | EP1414443A1 BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES |
| 05/06/2004 | EP1414432A2 Methods of use for novel sulfur containing organic nitrate compounds |
| 05/06/2004 | EP1414428A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs |
| 05/06/2004 | EP1414426A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 05/06/2004 | EP1307441B1 1,3-dioxolanes with antitussive activity |
| 05/06/2004 | EP1261600B1 Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 |
| 05/06/2004 | EP1257548B1 Benzofuran carboxamides and their therapeutic use |
| 05/06/2004 | EP1222162B1 Novel ltb4-antagonist, method for the production thereof and its use as a medicament |
| 05/06/2004 | EP1163237B1 Amide derivatives |
| 05/06/2004 | EP1047395B1 Mixture containing honey, at least one essential oil and/or at least one essential oil derivative |
| 05/06/2004 | CA2503588A1 Phenethanolamine derivative for the treatment of respiratory diseases |
| 05/06/2004 | CA2502453A1 Angiogenesis inducer |
| 05/06/2004 | CA2500836A1 Metal-containing materials, compositions and methods |
| 05/05/2004 | CN1494544A Alkoxy carbonylamino heteroaryl carboxylic acid derivatives as IP antagonists |
| 05/05/2004 | CN1494542A 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 05/05/2004 | CN1494539A Antagonists of MCP-1 function and methods of use thereof |
| 05/05/2004 | CN1494526A Inhibitor of monoamine uptake |
| 05/05/2004 | CN1494427A Medicament for treating asthma |
| 05/05/2004 | CN1493571A 木犀草素金属盐及其制备方法和用途 Luteolin and its preparation method and use salt |
| 05/05/2004 | CN1493351A Chinese medicine compound spraying agent for treating acute, chronic nasitis and its preparation method |
| 05/05/2004 | CN1493311A 咳喘药 Cough medicine |
| 05/05/2004 | CN1493296A Hemsleya amabilis drip pill and its preparation method |
| 05/05/2004 | CN1148369C 1,8-naphthyridine derivatives |
| 05/05/2004 | CN1148367C Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same |
| 05/05/2004 | CN1148350C Novel VLA-4 inhibitor: oMePUPA-V |
| 05/05/2004 | CN1148346C Hydrazine derivs. |
| 05/05/2004 | CN1148227C Therapeutic compound and its application |
| 05/05/2004 | CN1148222C Traditional Chinese medicine prepn. for treating acute and chronic bronchitis, and its prepn. method |
| 05/05/2004 | CN1148220C Antivirus antipyretic |
| 05/05/2004 | CN1148217C Chinese medicine for treating chronic bronchitis |
| 05/05/2004 | CN1148214C Medicine for curing bronchial asthma disease and its preparing method |
| 05/05/2004 | CN1148168C Micronised pharmaceutical compositions |
| 05/04/2004 | US6730696 Phospholipid derivatives of non-steroidal anti-inflammatory drugs |
| 05/04/2004 | US6730695 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for V1b and V1a arginine-vasopressin receptors |
| 05/04/2004 | US6730692 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 05/04/2004 | US6730664 The side-effects of chemotherapy are suppressed or reduced |
| 05/04/2004 | US6730505 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 05/04/2004 | US6730489 Antibodies to truncated VEGF-D and uses thereof |
| 05/04/2004 | US6730480 Sphingosine kinase enzyme |
| 05/04/2004 | US6730332 Synergistic aqueous extract from fruits of terminalia chebula, bark of albizia lebbeck, terminalia bellerica and emblica officinalis |
| 05/04/2004 | US6730325 Multiparticulate modified release composition |
| 05/04/2004 | US6730301 Mediating chemotaxis and activation of monocytes; athero-sclerosis; monocyte chemoattractant protein-1 (mcp-1) |
| 05/04/2004 | CA2213638C Aerosols containing nanoparticle dispersions |
| 05/04/2004 | CA2183234C Agent for prophylaxis and treatment of thromboxane a2-mediated diseases |
| 04/29/2004 | WO2004035581A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 04/29/2004 | WO2004035556A1 Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists |
| 04/29/2004 | WO2004035139A1 Regulation of mkk3 |
| 04/29/2004 | WO2004035092A2 Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases |
| 04/29/2004 | WO2004035080A1 Treatment of hypersensitivity conditions |
| 04/29/2004 | WO2004035048A1 Hepatic fibrosis inhibitor |
| 04/29/2004 | WO2004035044A1 Dry syrup preparation of procaterol comprising ascorbinic acid and citric acid |
| 04/29/2004 | WO2004035038A1 Therapeutic agent for chronic obstructive pulmonary disease |
| 04/29/2004 | WO2004019868A3 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 04/29/2004 | WO2004011402A3 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 04/29/2004 | WO2003104255A3 Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives as ligands for the neuropeptide y5 receptor |
| 04/29/2004 | WO2003099823A3 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 04/29/2004 | WO2003097649A3 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
| 04/29/2004 | WO2003093242A3 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/29/2004 | WO2003086282A3 Nitric oxide donors, compositions and methods of use |
| 04/29/2004 | WO2003042399A9 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 04/29/2004 | WO2003013537A9 Irinotecan for treatment of cancer |
| 04/29/2004 | WO2003013536A9 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 04/29/2004 | WO2003013535A9 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 04/29/2004 | WO2003013534A9 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 04/29/2004 | WO2003013533A9 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 04/29/2004 | WO2003009807A3 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |